Menu
CMS said new supplemental rebates drug manufacturers will provide to states through its GENEROUS pilot model will not affect 340B program ceiling prices. 

CMS Says New Medicaid Supplemental Rebate Model Will Not Affect 340B Ceiling Prices

Shannon Young, Associate Editor/Senior Writer 340B Report Views
The Trump administration’s new voluntary pilot plan to lower state Medicaid plans’ prescription drug spending by bringing prices in line [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Post Navigation

Oklahoma AG Appeals Ruling Against Contract Pharmacy Law, Pans Drug Industry’s Lawsuits Targeting State 340B Action

340B Agency Activities Resume After Congress Ends 43-Day Shutdown; Health Centers Get Short-Term Funding

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Quick verification required before signup

Site Footer Live